Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
SpiroxatrineCat. No. 0631 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Chemical Name: 8-[(2,3-Dihydro-1,4-benzodioxin-2-yl)methyl]-1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one |
Biological Activity
5-HT1A antagonist. More active and selective than spiperone. Also a very potent α2C adrenergic receptor antagonist.Technical Data
M.Wt:The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
References
Nelson and Taylor (1986) Spiroxatrine: a selective serotonin 1A receptor antagonist. Eur.J.Pharmacol. 124 207. PMID: 3720840.
Schoeffter and Hoyer (1988) Centrally acting hypotensive agents with affinity for 5-HT1A binding sites inhibit forskolin-stimulated adenylate cyclase activity in calf hippocampus. Br.J.Pharmacol. 95 975. PMID: 3207999.
Bylund et al (1992) Pharmacological characteristics of α2-adrenergic receptors: comparison of pharmacologically defined subtypes with subtypes identified by molecular cloning. Mol.Pharmacol. 42 1. PMID: 1353247.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: Spiroxatrine, supplier, Potent, α2C-adrenoceptor, alpha2C-adrenoceptor, alpah2c-adrenergic, a2c-adrenoceptor, a2c-adrenergic, antagonists, 5-HT1A, Receptors, Serotonin
Quick Order
Find multiple products by catalog number
Cardiovascular Guide
Request your free copy
Highlights over 250 products for cardiovascular research. Request a copy or view PDF today.
7-TM Receptor Signaling
Written by T. Kenakin et al
'Seven Transmembrane Receptor Signaling' highlights the multiple behaviors of 7-TMs including G-protein-dependent and -independent signaling as well as the concept of collateral efficacy
Neurobiology of Parkinson's Disease
Written by A. Schapira
'Neurobiology and Therapeutics of Parkinson's Disease' highlights the neurobiology of Parkinson's disease and summarizes current and novel therapeutic interventions.
Regulation of Vascular Reactivity by GPCRs
Written by J.J. Maguire and A.P. Davenport
'Regulation of Vascular Reactivity by G-protein-coupled Receptors' summarizes the key GPCRs regulating vascular reactivity.
Antidepressants - Current and Future Targets
Written by P. Skolnich et al
'Antidepressants - Current and Future Targets' provides an overview of the current and future targets for the treatment of major depressive disorder.
New Products in this Area
Long-acting β2 agonist; bronchodilator
Tocris Events
Win a Kindle
11th Congress of the French Neuroscience Society
May 21 - 24, 2013
Lyon, France
Booth Number: 32